<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553617</url>
  </required_header>
  <id_info>
    <org_study_id>VOLU-010-C P4</org_study_id>
    <nct_id>NCT01553617</nct_id>
  </id_info>
  <brief_title>VolulyteTM in Cardiac Surgery</brief_title>
  <official_title>Efficacy and Safety of Perioperative Infusion of 6 % Hydroxyethyl Starch 130/0.4 in an Isotonic Electrolyte Solution (VolulyteTM) vs. 5% HSA as Volume Replacement Therapy During Cardiac Surgery for Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the efficacy and safety of VolulyteTM and human albumin in elective
      open-heart surgery in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Calculated red blood cell loss</measure>
    <time_frame>up to 3rd postoperative day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemodynamics</measure>
    <time_frame>up to 3rd postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid input/output</measure>
    <time_frame>up to 3rd postoperative day</time_frame>
    <description>Quantity of total fluids administered and excreted or lost from beginning of anaesthesia until 3rd postoperative day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of vasoactive and inotropic drugs</measure>
    <time_frame>up to 3rd postoperative day</time_frame>
    <description>Type and amount of vasoactive and inotropic drugs administered from beginning of anaesthesia until 3rd postoperative day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
    <time_frame>up to day 28 after surgery</time_frame>
    <description>Serum creatinine concentration at day 28 after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
    <time_frame>up to 3rd postoperative day</time_frame>
    <description>set of standard laboratoy parameters before surgery and postoperatively until 3rd postop day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Heart; Dysfunction Postoperative, Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Volulyte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human serum albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human serum albumin (HSA 50g/L)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)</intervention_name>
    <description>Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day</description>
    <arm_group_label>Volulyte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human serum albumin</intervention_name>
    <description>Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day</description>
    <arm_group_label>Human serum albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female adult patients

          -  undergoing primary elective cardiac surgery applying extracorporeal circulation

          -  signed written informed consent

        Exclusion Criteria:

          -  known contraindication against scheduled medication

          -  pre-operative acute normovolaemic haemodilution or preoperative autologous blood
             donation

          -  planned systemic hypothermia (body temperature &lt; 30°C)

          -  expected time on ECC ≥ 2 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C Mazer</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Department of Anaesthesia, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

